Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-β-targeting component intended to both block tumor growth signaling and modulate the tumor microenvironment. The company is based in Boston and focuses on targeted oncology rather than commercial product sales at this stage.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -36.9 | — |
| Q2 2025 | 0 | — | -27.4 | — |
| Q3 2025 | 0 | — | -36.3 | — |
| Q4 2025 | 0 | — | -37.4 | — |
| Q1 2026 | 0 | — | -56.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: LB Pharmaceuticals Inc (LBRX), Safety Insurance Group, Inc. (SAFT), Healthcare Services Group, Inc. (HCSG), Kestra Medical Technologies, Ltd. (KMTS), ITG, Inc. (ITG), Omada Health, Inc. (OMDA)